XRAY vs LMAT

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 22, 2026

XRAY

50.2
AI Score
VS
XRAY Wins

LMAT

36.4
AI Score

Investment Advisor Scores

XRAY

50score
Recommendation
HOLD

LMAT

36score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric XRAY LMAT Winner
Revenue 1.78B 164.15M XRAY
Net Income 27.00M 32.85M LMAT
Gross Margin 51.7% 68.4% LMAT
Net Margin 1.5% 20.0% LMAT
Operating Income 47.00M 39.40M XRAY
ROE 2.0% 9.9% LMAT
ROA 0.5% 8.7% LMAT
Total Assets 5.20B 377.02M XRAY
Cash 239.00M 21.00M XRAY
Current Ratio 1.63 7.74 LMAT

Relative Price Performance (Last 90 Days)

XRAY 1M: -2.9% · 3M: -26.5% LMAT 1M: +5.9% · 3M: -10.7%

Current Technical Phase

XRAY

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 55

RSI (14): 55.1 · Price: $9.50

LMAT

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 61

RSI (14): 61.1 · Price: $85.33

Fundamentals Snapshot

Metric XRAY LMAT
Market Cap — —
Forward P/E 6.4 26.8
Trailing P/E — 29.2
Revenue (TTM) — —
Revenue Growth 0.0% 0.1%
Gross Margin 0.5% 0.7%
Operating Margin 0.1% 0.3%
EPS -2.73 2.87
Dividend Yield 0.04% 0.01%

Frequently Asked Questions

Based on our detailed analysis, XRAY is currently the stronger investment candidate, winning 4 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.